The Female Health Company to Present at Sidoti's Eighth Semi-Annual New York Micro-Cap Conference on May 9, 2014
CHICAGO, May 2, 2014 /PRNewswire/ -- The Female Health Company (NASDAQ-CM: FHCO), which manufactures and markets the FC2 Female Condom®, today announced that it will be presenting at Sidoti & Company's Eighth Semi-Annual Micro-Cap Conference on Friday, May 9, 2014. The conference will be held at the Grand Hyatt New York Hotel in midtown Manhattan.
The presentation by Karen King, Chief Executive Officer, and Michele Greco, Chief Financial Officer, is scheduled for 10:00 a.m. Eastern Daylight Time. Management will be available during the day for one-on-one meetings. Investors interested in arranging one-on-one meetings should contact their Sidoti representative.
About Sidoti & Company, LLC
Sidoti & Company, LLC, founded in 1999, continues to set the Wall Street standard for independent small-cap equity research, while rapidly becoming a driving force in micro-cap research, launching coverage of more than 500 small-cap and over 200 micro-cap companies since mid-2010. Its analysts mine dozens of industries to provide unbiased, institutional-quality research focusing on the investment merits of profitable small-cap companies, and it continues to expand its coverage of micro-cap equities. Sidoti's research is exclusively available to institutional investors, and its semi-annual conferences are unmatched on Wall Street.
About The Female Health Company
The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2). Since the Company began distributing FC2 in 2007, it has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The FC2 Female Condom® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.
Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated.
For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to FHCInvestor@femalehealthcompany.com
SOURCE The Female Health Company